David L Spriggs

US Patent:

20070269831, Nov 22, 2007

Filed:

Sep 10, 2004

Appl. No.:

10/595135

Inventors:

David Spriggs - New York NY, US
Jakob Dupont - Pelham NY, US

Assignee:

SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH - New York NY

International Classification:

G01N 33/574

US Classification:

435007100, 435007230

Abstract:

YKL-40 levels in serum and plasma samples provide as an indicator of both the presence of early stage ovarian cancer and of its aggressiveness. Thus testing for YKL-40 levels in patients at risk but not yet displaying symptoms associated with ovarian cancer, or in patients newly diagnosed with early stage ovarian cancer (Stage I or II) enhance both the detection of early stage ovarian cancer and selection of treatment protocols used for early stage ovarian cancer patients.

US Patent:

20130171152, Jul 4, 2013

Filed:

Mar 25, 2011

Appl. No.:

13/635090

Inventors:

David Spriggs - New York NY, US
Dharmarao Thapi - Bayside Hills NY, US

Assignee:

Memorial Sloan Kettering Cancer Center - New York NY

International Classification:

C07K 16/30

US Classification:

4241391, 5303879, 5303873, 435331, 536 2353, 436501, 435 723

Abstract:

The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to a polypeptide, or antigenic portion thereof, wherein the polypeptide is selected from a) MUC16 ectodomain polypeptide, b) MUC16 cytoplasmic domain polypeptide, and c) MUC16 extracellular domain polypeptide that contains a cysteine loop polypeptide. The invention's antibodies and compositions containing them are useful in diagnostic and therapeutic applications for diseases in which MUC16 is overexpressed, such as cancer.